0001720893
false
0001720893
2023-10-04
2023-10-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
October 4, 2023
BioXcel
Therapeutics, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-38410 |
|
82-1386754 |
(State
or other jurisdiction of
incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer Identification No.) |
555
Long Wharf Drive
New
Haven, CT 06511
(Address of principal executive offices, including
Zip Code)
(475)
238-6837
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed since
last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common
Stock, par value $0.001 |
|
BTAI |
|
The Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 | Regulation FD Disclosure. |
On October 4, 2023, BioXcel Therapeutics, Inc. (the “Company”)
provided the following business updates:
Late-Stage Clinical Programs: TRANQUILITY and SERENITY III
Agitation Associated with Mild to Moderate Dementia due to Probable
Alzheimer’s Disease (“AAD”):
Type B/Breakthrough Meeting on October 11
The Company plans to review its TRANQUILITY clinical trial program
with the U.S. Food and Drug Administration (“FDA”) and to discuss the data package required to support submission of an sNDA
for the approval of BXC501 for the acute treatment of agitation in mild to moderate dementia patients with probable Alzheimer’s
disease in assisted living facilities and at-home settings.
The briefing book submitted to FDA for the meeting includes results
from 11 double-blind, placebo-controlled, Phase 2 and 3 clinical trials evaluating the safety and efficacy of BXCL501. Trials with BXCL501
have enrolled more than 1,100 patients across multiple neuropsychiatric conditions and in healthy volunteers, and have shown no unexpected
safety signals, no reports of serious adverse events or falls related to the study drug, and no drug-related deaths, which is all consistent
with the known pharmacological effects of BXCL501.
Of the subjects who received various doses of BXCL501, 273 were over
60 years of age, and 204 were over 65 years of age. The TRANQUILITY I and TRANQUILITY II trials were placebo-controlled, showed statistically
significant separation from placebo in Positive and Negative Syndrome Scale-Excitatory Component (PEC) total score at two hours with the
60 mcg dose (primary endpoint), and had no unexpected safety findings. Data from TRANQUILITY I led the FDA to grant BXCL501 Breakthrough
Therapy designation for the acute treatment of agitation associated with dementia. Additionally, the efficacy results seen in TRANQUILITY
II after 12 weeks for all treated episodes was comparable to those observed after the first dose. Moreover, the adverse events (“AEs”)
observed after the first dose were similar to the AEs observed after all doses in TRANQUILITY II (443 episodes treated) and comparable
to the AEs observed in the single-dose TRANQUILITY I trial (100 episodes treated).
Ongoing Investigation and Third Party Audit in Connection with TRANQUILITY
II Trial
The Company is continuing its previously disclosed investigation into
protocol adherence and data integrity at a principal investigator’s trial site in connection with the TRANQUILITY II trial, and
an independent third party is auditing the data collected at that site. The Company’s ongoing investigation and/or the independent
audit may result in findings regarding the integrity of the trial data from this principal investigator’s site, the accuracy of
safety or efficacy findings, or the usability of the data in connection with a marketing application. Even if the Company’s investigation
and the independent audit conclude that data from the trial have not been affected or compromised by the principal investigator’s
actions or other deficiencies at the trial site, the FDA may not accept or agree with the Company’s conclusions or analyses, or
may interpret or weigh their importance differently and the Company may be unable to use some or all of the subject data generated at
this clinical site to support a marketing application. The Company can provide no assurance regarding the timing of the completion of
its own investigation or the independent audit of the trial site or the FDA’s views regarding the integrity of the data generated
by the subject principal investigator for the TRANQUILITY II trial.
At-Home Setting in Agitation Associated with Bipolar Disorders I
and II and Schizophrenia:
Type C Meeting on November 8
The Company will review
its SERENITY III program with the FDA on November 8, 2023 and plans to discuss the data
package required to support submission of an sNDA seeking approval of BXCL501 for the acute treatment of agitation associated with bipolar
disorders I and II and schizophrenia in the at-home setting. In addition, the Company plans to discuss the evaluation of the 80 mcg dose
of BXCL501 and several potential protocol amendments to the SERENITY III Part 2 trial. The Company identified the 80 mcg dose as
more favorable for further development based on pharmacokinetic-pharmacodynamic (PK-PD) modeling anchored by extensive data from studies
that evaluated the 60 mcg dose of BXCL501 (half of the lower approved IGALMI™ dose) as well as studies that evaluated the 120 mcg
and 180 mcg approved doses of IGALMI™.
The primary objective of Part 2 of SERENITY III is to assess safety
(the incidence of treatment-emergent adverse events), and the secondary objectives include various efficacy assessments.
IGALMI™ Market Exclusivity Strengthened: Two Notices of Allowance
Received
BioXcel Therapeutics recently received two NOAs1
from the U.S. Patent and Trademark Office for patent applications related to the method of use of sublingual dexmedetomidine
for the treatment of agitation associated with bipolar disorders and schizophrenia. When these patents are granted, the Company
plans to list them in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the “Orange
Book”) for IGALMI™. The Company now has four U.S. patents claiming formulations of dexmedetomidine with exclusivity
until 2039 currently listed in the Orange Book. The Company expects that these two new patents will expire no earlier than Dec. 29,
2037, subject to the patent term adjustment, patent term extension, and terminal disclaimers. These patents further broaden the scope
of intellectual property estate for IGALMI™ and for future potential indications.
Forward-Looking Statements
This Current Report on
Form 8-K (“Form 8-K”) includes “forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this Form 8-K other
than statements of historical fact should be considered forward-looking statements, including, without limitation, statements regarding:
the Company’s expected timing and outcome of discussions with FDA; the potential outcomes of the Company’s investigation
and third-party audit of a principal investigator’s site; the Company’s advancement of its product candidates for regulatory
approval; and the potential for the results from the Company’s completed, ongoing and proposed clinical trials to support regulatory
approvals for its product candidates, including the results from the TRANQUILITY II and SERENITY III clinical trials. The words “anticipate,”
“believe,” “can,” “continue,” “could,” “designed,” “estimate,”
“expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,”
“possible,” “potential,” “predict,” “project,” “should,” “target,”
“will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking
statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections,
objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-
looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company
believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize
its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such
forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its
incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its ability to
successfully negotiate amended terms under the financing agreements to be able to access funding and to obtain relief under financial
covenants; its significant indebtedness and potential payment obligations related to such indebtedness and other contractual obligations;
risks associated with the strategic reprioritization; its limited experience in drug discovery and drug development; risks related to
the TRANQUILITY II Phase 3 trial and related audit; its dependence on the success and commercialization of IGALMI™, BXCL501, BXCL502
BXCL701 and BXCL702 and other product candidates; its lack of experience in marketing and selling drug products; the risk that IGALMI
or the Company’s product candidates may not be accepted by physicians or the medical community in general; the failure of preliminary
data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict
future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its
clinical trials; undesirable side effects caused by the Company’s product candidates; its novel approach to the discovery and development
of product candidates based on EvolverAI; the significant influence of and dependence on BioXcel LLC; its exposure to patent infringement
lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches
or cyber-attacks, if any; impacts from the COVID-19 pandemic; risks associated with the increased scrutiny relating to environmental,
social and governance (ESG) matters; its ability to commercialize its product candidates; and the other important factors discussed under
the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, which
is accessible on the Securities and Exchange Commission’s website at www.sec.gov. These
and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made
in this Form 8-K. Any such forward-looking statements represent management’s estimates as of the date of this Form 8-K.
While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims
any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon
as representing the Company’s views as of any date subsequent to the date of this Form 8-K.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: October 4, 2023 |
|
BIOXCEL THERAPEUTICS, INC. |
|
|
|
|
|
/s/ Richard Steinhart |
|
By: |
Richard Steinhart |
|
Title: |
Chief Financial Officer |
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
BioXcel Therapeutics (NASDAQ:BTAI)
過去 株価チャート
から 4 2024 まで 5 2024
BioXcel Therapeutics (NASDAQ:BTAI)
過去 株価チャート
から 5 2023 まで 5 2024